Cargando…
Therapeutic potential of a TrkB agonistic antibody for Alzheimer's disease
Repeated failures of “Aβ-lowering” therapies call for new targets and therapeutic approaches for Alzheimer's disease (AD). We propose to treat AD by halting neuronal death and repairing synapses using a BDNF-based therapy. To overcome the poor druggability of BDNF, we have developed an agonisti...
Autores principales: | Wang, Shudan, Yao, Hongyang, Xu, Yihua, Hao, Rui, Zhang, Wen, Liu, Hang, Huang, Ying, Guo, Wei, Lu, Bai |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Ivyspring International Publisher
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7295064/ https://www.ncbi.nlm.nih.gov/pubmed/32550908 http://dx.doi.org/10.7150/thno.44165 |
Ejemplares similares
-
A Monoclonal Antibody TrkB Receptor Agonist as a Potential Therapeutic for Huntington’s Disease
por: Todd, Daniel, et al.
Publicado: (2014) -
Do Small Molecules Activate the TrkB Receptor in the Same Manner as BDNF? Limitations of Published TrkB Low Molecular Agonists and Screening for Novel TrkB Orthosteric Agonists
por: Pankiewicz, Piotr, et al.
Publicado: (2021) -
Activation of TrkB/Akt signaling by a TrkB receptor agonist improves long-term histological and functional outcomes in experimental intracerebral hemorrhage
por: Wu, Chun-Hu, et al.
Publicado: (2019) -
Actions of the TrkB Agonist Antibody ZEB85 in Regulating the Architecture and Synaptic Plasticity in Hippocampal Neurons
por: Tacke, Charlotte, et al.
Publicado: (2022) -
Optimized TrkB Agonist Ameliorates Alzheimer’s Disease Pathologies and
Improves Cognitive Functions via Inhibiting Delta-Secretase
por: Chen, Chun, et al.
Publicado: (2021)